April 24, 2017

The transaction is expected to close by early 2018 and to be accretive in 2018 to Fresenius Group net income and EPS, excluding integration costs.

April 21, 2017

Renflexis, marketed by Merck and developed by South Korea's Samsung Bioepis, is the second FDA-approved biosimilar to Johnson & Johnson’s Remicade.

April 21, 2017

Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg are the generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering. 

April 20, 2017

Drugs are used for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist combination.

April 20, 2017

Japanese generic pharmaceutical manufacturer Sawai Pharmaceutical will purchase the assets and plans a major expansion in the U.S. market.

April 19, 2017

Vilazodone hydrochloride tablets, the therapeutic equivalent to the reference-listed drug product Viibryd tablets of Forest Labs, treats depression.

April 19, 2017

According to Argentum, the agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the patents covering Restasis. 

April 19, 2017

Daewoong Pharmaceutical’s Meroprenem is a generic of Merem, developed by AstraZeneca, as a Carbapenem-series antibiotic widely used in hospitals to treat various ailments ranging from bacterial infections to general diseases.

April 18, 2017

It is uncertain if the United States will attempt a similar tactic, but Trump Administration office have repeatedly said they want to lower drug prices by having the Food and Drug Administration approve generic drugs faster.

April 18, 2017

In fact, J&J stated is now including the estimated impact of the Actelion transaction in its financial guidance.

April 18, 2017

The New York Times is reporting that Philadephia-based generics company Lannett continues to raise prices on its drugs, even as the Justice Department is set to launch an anitrust investigations an Connecticut’s attorney general undertakes a drug price investigation into the company. Among the generics that have seen prices increase recently was anti-psychotic fluphenazine, which went from $43.50 to $870 for 100 10-mg capsules in 2016. (New York Times)

 

April 17, 2017

Baxter anticipates launching seven to nine new products annually over the next few years, increasing to 10 to 15 anticipated new product launches a year beyond 2019.

April 14, 2017

State senators voted 22-9 in favor of approving a measure intended to help ease the state’s growing opioid epidemic.

April 11, 2017

Mometasone furoate, available in 50 mcg/spray strength, is an AB-rated therapeutic equivalent to Nasonex.

April 10, 2017

Specialty pharmaceutical company could be acquired by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.

April 10, 2017

Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg is indicated for the treatment of major depressive disorder and prevention of seasonal affective disorder in adults.

April 10, 2017

Alembic Pharmaceuticals’ Fluoxetine Hydrochloride tablets are used for the treatment of depression and panic disorder.

April 10, 2017

Multiple news outlets state company could receive $2 billion in proceeds for the company it acquired from Merck KGaA’s Merck Serono in 2010.

April 5, 2017

Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug, Epzicom Tablets, 600 mg/300 mg of ViiV Healthcare.

April 4, 2017

Rivelsa is an estrogen/progestin COC intended for use by women to prevent pregnancy.

March 30, 2017

Abacavir Sulfate and Lamivudine Tablets, 600 mg/300 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Epzicom Tablets of ViiV Healthcare.

March 30, 2017

Abacavir and Lamivudine tablets, 600mg/300mg, are the AB rated generic equivalent of ViiV Healthcare's Epzicom tablets, 600mg/300mg.

March 29, 2017

Twenty-year industry veteran will be responsible for the retail generic business.

March 29, 2017

QuickFire Challenge winners will receive grants totaling up to $200,000, entrance to a Johnson & Johnson Innovation – JLABS facility and/or mentoring from Johnson & Johnson Innovation.